PT - JOURNAL ARTICLE AU - Baback Roshanravan AU - Sophia Z. Liu AU - Eric G. Shankland AU - John K. Amory AU - H. Thomas Robertson AU - David J. Marcinek AU - Kevin E. Conley TI - <em>In Vivo</em> Mitochondrial ATP Production Is Improved in Older Adult Skeletal Muscle After a Single Dose of Elamipretide in a Randomized Trial AID - 10.1101/2020.09.30.20200493 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.30.20200493 4099 - http://medrxiv.org/content/early/2020/10/02/2020.09.30.20200493.short 4100 - http://medrxiv.org/content/early/2020/10/02/2020.09.30.20200493.full AB - Background Loss of mitochondrial function contributes to fatigue, exercise intolerance and muscle weakness, and is a key factor in the disability that develops with age and a wide variety of chronic disorders. Here, we describe the impact of a first-in-class cardiolipin-binding compound that is targeted to mitochondria and improves oxidative phosphorylation capacity (Elamipretide, ELAM) in a randomized, double-blind, placebo-controlled clinical trial.Methods Non-invasive magnetic resonance and optical spectroscopy provided measures of mitochondrial capacity (ATPmax) with exercise and mitochondrial coupling (ATP supply per O2 uptake; P/O) at rest. The first dorsal interosseous (FDI) muscle was studied in 39 healthy older adult subjects (60 to 85 yrs of age; 46% female) who were enrolled based on the presence of poorly functioning mitochondria. We measured volitional fatigue resistance by force-time integral over repetitive muscle contractions.Results A single ELAM dose elevated mitochondrial energetic capacity in vivo relative to placebo (ΔATPmax; P=0.055, %ΔATPmax; P=0.045) immediately after a 2-hour infusion. No difference was found on day 7 after treatment, which is consistent with the half-life of ELAM in human blood. No significant changes were found in resting muscle mitochondrial coupling. Despite the increase in ATPmax there was no significant effect of treatment on fatigue resistance in the FDI.Conclusions These results highlight that ELAM rapidly and reversibly elevates mitochondrial capacity after a single dose. This response represents the first demonstration of a pharmacological intervention that can reverse mitochondrial dysfunction in vivo immediately after treatment in aging human muscle.Competing Interest StatementBaback Roshanravan, David J. Marcinek, and Kevin E. Conley have served as paid consultants for Stealth BioTherapeutics. The study was funded by Stealth BioTherapeutics.Clinical TrialNCT02245620Funding StatementThis work was supported by Stealth Biotherapeutics; National Institutes of Health grants (5T32AG5738, UL1TR000423, 1S10OD016201, K23DK099442, P01AG001751); the Department of Radiology and the Office of the Provost of the University of Washington. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Western Institutional Review Board approved this clinical study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request.